Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Christina A. Chao
G1T48, an Oral Selective Estrogen Receptor Degrader, and the CDK4/6 Inhibitor Lerociclib Inhibit Tumor Growth in Animal Models of Endocrine-Resistant Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
Related publications
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
A First in Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for HR+/HER2− Advanced Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Synthetic Cannabinoid Receptor Agonists Inhibit Tumor Growth and Metastasis of Breast Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer
Impact of Adding the Multikinase Inhibitor Sorafenib to Endocrine Therapy in Metastatic Estrogen Receptor-Positive Breast Cancer
Future Oncology
Medicine
Cancer Research
Oncology
Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Extracellular Alkaline pH Leads to Increased Metastatic Potential of Estrogen Receptor Silenced Endocrine Resistant Breast Cancer Cells
PLoS ONE
Multidisciplinary
